Astrana Health (ASTH) vs P3 Health Partners (PIII)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Astrana Health (ASTH) has outperformed P3 Health Partners (PIII) over the past year, gaining 23.4% versus a loss of 45.9%. Over five years, ASTH leads with a -47.5% price change compared with -99.0% for PIII. Astrana Health is the larger company by market cap ($1.86 billion vs $1.01 billion), about 1.8 times the size.
Astrana Health converts more of its revenue into profit, with a net margin of 0.7% versus -10.1%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ASTH | PIII |
|---|---|---|
| Share price | $37.55 | $4.95 |
| Market cap | $1.86B | $1.01B |
| 1-day change | +4.68% | -6.78% |
| YTD return | +51.35% | +41.83% |
| 1-year return | +23.44% | -45.90% |
| 5-year return | -47.48% | -99.00% |
| P/E ratio (TTM) | 45.24 | — |
| Forward P/E | 10.33 | — |
| EPS (TTM) | $0.83 | $-33.02 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $3.18B | $1.46B |
| Revenue growth (YoY) | +56.39% | -2.76% |
| Net income (latest FY) | $22.49M | $-147.95M |
| Gross margin | 10.73% | — |
| Operating margin | 2.47% | -18.53% |
| Net margin | 0.71% | -10.14% |
| 52-week high | $51.60 | $16.89 |
| 52-week low | $18.08 | $1.52 |
| Distance from 52-week high | -27.23% | -70.69% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +37.60% | +263.64% |
| Average volume | 458.06K | 32.38K |
| Shares outstanding | 49.60M | 3.91M |
| Employees | 3,000 | 320 |
| Sector | Consumer Discretionary | Health Care |
| Industry | Professional Services | Medical/Nursing Services |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ASTH has outperformed PIII by 69.3 percentage points over the past year.
- Astrana Health is more profitable, keeping 0.7 cents of every revenue dollar as net income versus -10.1 cents for P3 Health Partners.
- Astrana Health grew revenue faster in its latest fiscal year (+56.39% vs -2.76%).
- The two companies sit in different sectors: Astrana Health in Consumer Discretionary and P3 Health Partners in Health Care.
About Astrana Health
ASTH stock →Astrana Health, Inc., a healthcare management company, provides medical care services in the United States. The company operates through three segments: Care Partners, Care Delivery, and Care Enablement.
Consumer Discretionary · Professional Services · 3,000 employees
About P3 Health Partners
PIII stock →P3 Health Partners Inc., a patient-centered and physician-led population health management company, provides superior care services in the United States. It operates clinics and wellness centers.
Health Care · Medical/Nursing Services · 320 employees
ASTH vs PIII FAQ
Which is bigger, Astrana Health or P3 Health Partners?
Astrana Health (ASTH) is larger, with a market capitalization of $1.86B compared with $1.01B for P3 Health Partners (PIII).
Which stock has performed better over the past year, ASTH or PIII?
ASTH returned +23.44% over the past 12 months, compared with -45.90% for PIII (price return, excluding dividends). Past performance does not predict future results.
Are Astrana Health and P3 Health Partners in the same industry?
No. Astrana Health is in the Consumer Discretionary sector, while P3 Health Partners is in Health Care.